Analysis of relationship between immune-related LncRNA and prognosis of clear cell renal cell carcinoma and establishment of predictive scoring model
-
摘要: 目的 探讨肾透明细胞癌(clear cell renal cell carcinoma，ccRCC)中免疫相关LncRNA表达与肿瘤预后的关系，并构建预后相关的预测评分模型。方法 从TCGA数据中下载537例ccRCC转录组测序数据及相应的临床预后信息，采用R软件和Perl软件利用生物信息学方法提取ccRCC免疫相关LncRNA，使用单因素和多因素Cox回归分析预后相关LncRNA，并构建预测模型，采用Kaplan-Meier分析预测模型与肿瘤预后相关性并绘制生存曲线，同时使用ROC曲线评估预测模型的准确性。结果 通过单因素和多因素Cox回归分析确定7个免疫预后相关LncRNA，并构建预测评分模型，根据患者预后评分将患者分为高风险组和低风险组，生存曲线显示两组患者预后差异有统计学意义(P< 0.05)，预测评分模型ROC曲线下面积(AUC)为0.8，多因素Cox回归分析风险评分为ccRCC预后的独立危险因素。结论 ccRCC中7个免疫相关的LncRNA与预后显著相关，基于其构建的预测评分模型可以有效预测ccRCC的预后，可作为其独立预后生物标志物。Abstract: Objective To investigate the relationship between immune-related LncRNA expression and tumor prognosis in clear cell renal cell carcinoma (ccRCC), and construct a prognostic-related predictive scoring model.Methods The transcriptome sequencing data of 537 cases of ccRCC and the corresponding clinical prognosis information were downloaded from the TCGA data, and R software and Perl software were used to extract the immune-related LncRNAs of renal clear cell carcinoma using bioinformatics methods. Single factor and multiple factors Cox regression analysis were used to analyse prognostic-related LncRNA, and construct a prediction model. Kaplan-Meier was used to analyze the correlation between the prediction model and tumor prognosis and the survival curve was drawn, and the ROC curve was used to evaluate the accuracy of the prediction model.Results Seven immune prognosis-related LncRNAs were determined through univariate and multivariate Cox regression analysis, and a predictive scoring model was constructed. Patients were divided into high-risk groups and low-risk groups based on patient prognosis scores. The survival curve showed that the prognosis of the two groups was statistically significant (P< 0.05), the area under the ROC curve of the predictive scoring model AUC was 0.8, and the multivariate Cox regression analysis risk score was an independent risk factor for the prognosis of ccRCC.Conclusion Seven immune-related LncRNAs in ccRCC are significantly related to the prognosis. The prediction scoring model constructed based on them can effectively predict the prognosis of ccRCC and can be used as its independent prognostic biomarkers.
-
Key words:
- renal clear cell carcinoma /
- LncRNA /
- immunity /
- prognosis /
- prediction model
-
-
表 1 单因素Cox回归分析筛选ccRCC免疫预后相关LncRNA
LncRNA HR 95%CI P值 LINC01963 0.57 0.41~0.80 < 0.01 AC092119.2 2.19 1.64~2.91 < 0.01 LINC00886 0.51 0.34~0.76 < 0.01 AL139351.1 1.88 1.52~2.32 < 0.01 LINC01788 0.50 0.34~0.73 < 0.01 LENG8-AS1 1.47 1.21~1.79 < 0.01 AC024060.1 2.13 1.71~2.65 < 0.01 AL139089.1 2.00 1.50~2.68 < 0.01 ZNF503-AS1 0.29 0.18~0.48 < 0.01 AC008906.1 1.86 1.35~2.57 < 0.01 FOXD2-AS1 2.68 1.92~3.76 < 0.01 
下载: 导出CSV
表 2 多因素Cox回归分析筛选ccRCC构建预测评分模型的免疫相关LncRNA
LncRNA β HR 95%CI P值 LINC01963 -0.37 0.69 0.48~0.98 0.04 AL139351.1 0.29 1.34 1.05~1.71 0.02 LINC01788 -0.41 0.67 0.46~0.96 0.03 LENG8-AS1 -0.40 0.68 0.46~0.99 0.04 AC024060.1 0.52 1.68 1.13~2.50 0.01 ZNF503-AS1 -0.95 0.39 0.23~0.66 < 0.05 FOXD2-AS1 0.63 1.88 1.21~2.91 < 0.05
下载: 导出CSV
-
[1] Capitanio U, Montorsi F. Renal cancer[J]. Lancet, 2016, 387(10021): 894-906. doi: 10.1016/S0140-6736(15)00046-X
[2] Pang C, Guan Y, Li H, et al. Urologic cancer in China[J]. Jpn J Clin Oncol, 2016, 46(6): 497-501. doi: 10.1093/jjco/hyw034
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
[4] 董良, 王伟英. 晚期肾透明细胞癌药物治疗进展[J]. 临床泌尿外科杂志, 2020, 35(9): 758-763. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202009020.htm
[5] Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[J]. Science, 2018, 359(6377): 801-806. doi: 10.1126/science.aan5951
[6] Topalian SL, Hodi FS, Brahmer JR, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab[J]. JAMA Oncol, 2019, 5(10): 1411-1420. doi: 10.1001/jamaoncol.2019.2187
[7] Goleva E, Lyubchenko T, Kraehenbuehl L, et al. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy[J]. Ann Allergy Asthma Immunol, 2021, 126(6): 630-638. doi: 10.1016/j.anai.2021.03.003
[8] Ueda K, Suekane S, Kurose H, et al. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma[J]. Urol Oncol, 2018, 36(11): 499. e9-499. e16. doi: 10.1016/j.urolonc.2018.07.003
[9] Chen L, Zhu D, Feng J, et al. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients[J]. Cancer Cell Int, 2019, 19: 101. doi: 10.1186/s12935-019-0813-2
[10] Iacovelli R, Nolè F, Verri E, et al. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis[J]. Target Oncol, 2016, 11(2): 143-148. doi: 10.1007/s11523-015-0392-7
[11] Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function[J]. Nat Rev Genet, 2016, 17(1): 47-62. doi: 10.1038/nrg.2015.10
[12] 林其玲, 陈畅. lncRNA LUCAT1通过靶向调控miR-199a-5p/HIF-1α促进肾透明细胞癌786-O细胞的增殖和迁移[J]. 中国肿瘤生物治疗杂志, 2020, 27(3): 273-281. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202003010.htm
[13] 仙淑丽, 罗清琼. LncRNA SNHG1通过吸附miR-199a-3p促进肾透明细胞癌细胞迁移和侵袭[J]. 解剖学研究, 2019, 41(3): 222-225. https://www.cnki.com.cn/Article/CJFDTOTAL-GDJP201903017.htm
[14] 张萌萌, 田孟真, 宋建忠, 等. lncRNANONHSAT113026在肾透明细胞癌中的表达及功能[J]. 现代肿瘤医学, 2019, 27(16): 2894-2899. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201916023.htm
[15] Carlevaro-Fita J, Liu L, Zhou Y, et al. LnCompare: gene set feature analysis for human long non-coding RNAs[J]. Nucleic Acids Res, 2019, 47(W1): W523-W529. doi: 10.1093/nar/gkz410
[16] Hahn AW, Klaassen Z, Agarwal N, et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis[J]. Eur Urol Oncol, 2019, 2(6): 708-715. doi: 10.1016/j.euo.2019.09.002
[17] 江卫星, 寿建忠. 转移性肾细胞癌免疫治疗的现状与进展[J]. 中华泌尿外科杂志, 2017, 38(7): 555-558. doi: 10.3760/cma.j.issn.1000-6702.2017.07.022
[18] Wang ZL, Wang Z, Li GZ, et al. Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma[J]. Front Immunol, 2019, 101756.
[19] Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of Long Noncoding RNAs[J]. Annu Rev Immunol, 2017, 35177-198.
[20] 王尧, 周旻, 柳子川, 等. 免疫相关LncRNA与膀胱癌预后关系分析及预测模型建立[J]. 遵义医科大学学报, 2020, 43(1): 76-80. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYB202001018.htm
[21] Xing L, Zhang X, Chen A. Prognostic 4-lncRNA-based risk model predicts survival time of patients with head and neck squamous cell carcinoma[J]. Oncol Lett, 2019, 18(3): 3304-3316.
[22] Qu L, Wang ZL, Chen Q, et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma[J]. Eur Urol, 2018, 74(6): 756-763. doi: 10.1016/j.eururo.2018.07.032
[23] 胡增涛, 关沧海, 赵俞乔. FOXD2-AS1在肿瘤中的功能与调控机制的研究进展[J]. 医学研究生学报, 2019, 32(11): 1207-1211. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYB201911019.htm
[24] Liu Z, Zhou W, Lin C, et al. Dysregulation of FOXD2-AS1 promotes cell proliferation and migration and predicts poor prognosis in oral squamous cell carcinoma: a study based on TCGA data[J]. Aging(Albany NY), 2020, 13(2): 2379-2396.
[25] Li K, Han H, Gu W, et al. Long non-coding RNA LINC01963 inhibits progression of pancreatic carcinoma by targeting miR-641/TMEFF2[J]. Biomed Pharmacother, 2020, 129110346.
[26] He H, Wu S, Ai K, et al. LncRNA ZNF503-AS1 acts as a tumor suppressor in bladder cancer by up-regulating Ca(2+)concentration via transcription factor GATA6[J]. Cell Oncol(Dordr), 2020
-
图(5)
表(2)
计量
- 文章访问数: 1208
- PDF下载数: 197
- 施引文献: 0